INTRODUCTION
Human cytomegalovirus (CMV), like all herpesviruses, establishes a latent infection for the life of the host, and can periodically reactivate in the immunologically normal host (1, 2) . As an opportunistic pathogen, CMV infection causes significant morbidity and mortality in immunocompromised populations including transplant recipients, the developing fetus, and HIV-infected individuals. There is also increasing evidence to associate CMV infection with inflammatory-related diseases (3, 4, 5, 6, 7, 8, 9) . The mechanisms through which CMV affects the pathogenesis of these inflammatory diseases are for the most part unknown (10).
Vascular complications and transplant loss have been linked with CMV infection.
Specific examples of disorders where CMV may play a role include coronary artery disease, restenosis following angioplasty procedures, transplant vascular sclerosis (TVS) in chronic graft rejection, and CMV-associated systemic sclerosis (7, 8, 9, 11, 12, 13, 14, 15, 16). Prior infection with CMV has been shown to be a strong independent risk factor for restenosis (7, 8) . CMV has also been found in atherosclerotic lesions, and encodes several gene products to modulate the immune cell responses and vascular cell activities Additionally, cytomegalovirus-mediated upregulation of chemokine expression including fractalkine correlates with the acceleration of chronic rejection in a rat heart transplant model (17, 32).
In our research, we have hypothesized that CMV-associated chronic endothelial cell inflammation and damage is mediated through induction of chemokines produced by activated endothelium, where endothelial cells are activated by the cytokine response from CMV antigen-specific T-cell stimulation. We have reported that the host CD4 + Tcell response to CMV antigen can produce IFNγ and TNFα at levels sufficient to drive induction of fractalkine, a key marker of inflammation in endothelial cells (10, 27, 33).
In many seropositive individuals, a relatively high percentage of the host T-cell response is invested in recognition of CMV antigens, emphasizing the potential of the host immune system to respond aggressively to CMV and contribute to a process of vascular inflammation leading to endothelial damage (34, 35, 36) . We have also observed a major pathogenic effect where endothelial cell damage and loss follow the induction of fractalkine and upregulation of cell adhesion markers in the presence of PBMCs from donors with relatively higher frequencies of CMV-specific T cells (37). These previous observations support the hypothesis that the endothelial damage is the result of a chemokine-mediated immunopathogenic effect. The current research was designed to test the role of chemokine interactions in mediating this damage process and to identify only.
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Primary human aortic endothelial cells (AECs) and culture medium were purchased from Clonetics (San Diego, CA); cells were used at low passage. All experiments were repeated with at least two different donors of AECs.
Co-cultures of PBMCs or subset populations with AEC monolayers. Co-cultures were established with resting confluent primary AEC monolayers, overlaid with either 1 x 10 6 PBMC or CD4 + cells, except where specified. Co-cultured cells were stimulated with heat-inactivated CMV strain AD169, and incubated in a humidified incubator for 72
hours at 37°C in 5% CO 2 . Co-cultures were maintained in a 50:50 mix of RPMI/10%
FCS and EGM-2 media/2% FCS (Clonetics) to support both cell types.
Transwell migration assays and specific antibody neutralization assays. The transwell inserts were 6.5 mm diameter, 5 micron pore size polycarbonate membranes, in 24-well polystyrene plates available from CoStar/Corning, Inc. #3421 (Corning, NY).
Co-culture supernatants or control media samples were loaded into lower well chambers.
Supernatants were prepared from either CMV seropositive or seronegative donor PBMCs co-cultured with endothelial monolayers and stimulated with CMV antigen. For transwell migration assays, 4 x 10 6 PBMCs in a 150 µl volume of control media were loaded into the upper chamber well inserts of 24-well transwell migration assay plates and incubated for 3 hours. For each assay, three replicate wells were set up and aliquots of the transmigrated populations were counted from each well independently and reported as the mean of the migrated cell number per ml (+/-SD).
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For personal use at PENN STATE UNIVERSITY on February 23, 2013. Endothelial damage assays and specific antibody blocking assays. A two-step assay for endothelial damage was used. First, PBMCs were set up in transwell migration assays as described above using co-culture supernatants previously collected from endothelial monolayers activated by CD4 + T cell response to CMV antigen. In a parallel series of assays, PBMCs were treated with specific blocking antibody directed against CX 3 CR1 or RANTES, compared to untreated controls. PBMC samples were then placed in transwell chambers, over co-culture supernatants or control media. In the second step, the transmigrated cell populations were collected and placed onto previously activated endothelial cell monolayers and induced for fractalkine. Endothelial cell damage and destruction were monitored over time, and the results compared using the different antibodies to block specific chemokine receptor-ligand interactions. Increased cell migration together with upregulation of cell adhesion markers indicated this damage occurred through a chemokine-mediated process (37). Because the endothelial damage occurred consistently with donors having a high CMV-specific T-cell response, we decided to focus further experiments on using these donors to study the chemokine and immune effector cells involved in endothelial damage.
For these experiments, PBMCs were collected from CMV seropositive donors with a high T cell frequency to CMV, and added as suspension cell cultures to primary aortic endothelial cell monolayer cultures (AECs). High CMV-specific T-cell response donors were defined as those donor PBMCs that produced high levels of fractalkine and other chemokines in culture (37). The cultures were treated with heat-inactivated CMV to stimulate CMV antigen-specific CD4 + T-cells. By day three of co-culture, the fractalkine levels secreted into the culture supernatants had reached peak levels (data not shown). RANTES, and MIP-1β (37). Of the elevated chemokines, fractalkine was detected at the highest levels in antigen-stimulated cultures (mean of 210 ng/ml) whereas it was undetectable in control cultures. The mean induction levels (by day 3 in co-culture for these high T cell response donors) of MIP-1β was 5,500 pg/ml and 28,000 pg/ml for RANTES; both were undetectable in control cultures (37). The high level of induction of fractalkine between antigen-stimulated and unstimulated conditions, together with the endothelial damage suggested that fractalkine might play a critical role in coordinating the events associated with the endothelial cell destruction. RANTES was also selected only.
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Specific blocking antibody assays were used in transwell assays to determine the relative contribution of fractalkine and RANTES in attracting PBMCs. Because only the fractalkine-induced cultures from CMV seropositive donors were associated with endothelial damage, we focused on using those culture supernatants for the endothelial damage assays. Results from the transwell migration assays show that chemokines present in the co-culture supernatants can support chemoattraction of PBMCs (Figure 3) .
The highest numbers of transmigrated cells (9 x 10
5 + /-9.89 x 10 4 cells per ml) were observed when there was no antibody treatment to interfere with chemokine functions (Figure 3) . In contrast, lower numbers of transmigrated cells were observed in the chemokine-negative control media, at 2.9 x 10 5 ( + /-6 x 10 4 ) cells/ml (data not shown).
Using blocking antibody targeting CX 3 CR1 present on PBMCs, a 65% decrease was seen in the total number of transmigrated cells for the CX 3 CR1 blocked sample (Figure 3) . Although there was a decline in migrated cells, the overall contribution of RANTES to chemoattraction of PBMCs in co-culture was consistently less than that of fractalkine. This is emphasized again using a combination of antibodies against CX 3 CR1
and RANTES where the total number of transmigrated cell populations was decreased by a mean of 71%, compared to a mean of 65% for blocking CX 3 CR1 alone (Figure 3) .
Results using an anti-CCR5 block were consistent with those using the anti-RANTES block (data not shown). These findings indicate that the fractalkine-CX 3 CR1 interaction plays a central role in chemoattraction of PBMC populations while RANTES plays less of a role. (+/-3.9)% decrease with the anti-RANTES block.
The CX 3 CR1-specific CD14 + cells were examined for cell migration response effects using a CX 3 CR1 block to check for consistency of the CX 3 CR1 response. For Using a two-step assay for endothelial damage, transmigrated PBMC populations were collected and tested for the ability to mediate endothelial cell damage. In a parallel series of assays, PBMCs were treated with specific antibody directed against CX 3 CR1, RANTES, or CX 3 CR1 plus RANTES as a dual block, compared to untreated controls.
Extensive damage and loss of the endothelial cell monolayers were observed in the positive control samples (Figure 7) . In contrast, protection against endothelial damage was observed in the presence of the anti-CX 3 CR1 blocked samples where the endothelial monolayers were intact, similar to the untreated negative control. In the anti-RANTES block treatment, only partial protection was observed; cell destruction and loss were present albeit to a lesser extent than what was observed in untreated control wells. The dual blocking treatment against CX 3 CR1 and RANTES was protective against endothelial cell damage. The isotype control treated sample was similar to the positive untreated control, indicating that non-specific antibody binding effects could be ruled out. PBMCs using untreated co-culture supernatants; Isotype control: PBMCs treated with isotype control antibodies for CX 3 CR1-specific and RANTES-specific neutralizing antibodies, followed by transmigration into co-culture supernatants; Anti-CX 3 CR1 block: PBMCs treated with neutralizing antibody specific for CX 3 CR1, followed by transmigration into co-culture supernatants; Anti-RANTES block: PBMCs treated with neutralizing antibody specific for RANTES, followed by transmigration into co-culture supernatants; Dual block: PBMCs treated with both neutralizing antibody specific for CX 3 CR1 and neutralizing antibody specific for RANTES, followed by transmigration into co-culture supernatants. Extensive endothelial damage and loss are seen in positive control, isotype control, and anti-RANTES block. In contrast, protection against endothelial damage is observed in the presence of the anti-CX 3 CR1 blocked samples. 
